Publications (25) View all
-
Article: Biosimilars of filgrastim in ASCT: Reduction in G-CSF costs, but similar effects on bone marrow recovery.
[show abstract] [hide abstract]
ABSTRACT: Abstract G-CSFs enhance bone marrow (BM) recovery after autologous stem cell transplantation (ASCT) in lymphoma and myeloma patients. Few publications exist that discuss the use of filgrastim biosimilars after ASCT. We conducted a single-center retrospective study with lymphoma and myeloma patients treated in Brest Hospital to assess the cost reductions related to and the efficiency and safety of filgrastim biosimilars. We identified 65 patients with lymphoma or myeloma treated with filgrastim biosimilars for ASCT and compared nineteen parameters of these patients, including BM recovery, side effects, infectious complications and treatment costs, with published historical data on a cohort of 50 patients treated with classical filgrastim. We observed a significant reduction of G-CSF costs in both groups but did not observe a change in total hospitalization costs (representing less than 2% of the costs) between groups. Additionally, we did not observe differences between the two groups in BM recovery, infectious complications, side effects or the other studied parameters. In this retrospective study, the absence of differences between groups after ASCT in lymphoma and myeloma led us to believe that these drugs could be safely and effectively used for such indications without a significant impact on hospitalization costs. A prospective study should be conducted to confirm our results.Leukemia & lymphoma 04/2013; · 2.40 Impact Factor -
Article: A novel cationic lipophosphoramide with diunsaturated lipid chains: synthesis, physicochemical properties, and transfection activities.
[show abstract] [hide abstract]
ABSTRACT: Cationic lipophosphoramidates constitute a class of cationic lipids we have previously reported to be efficient for gene transfection. Here, we synthesized and studied a novel lipophosphoramidate derivative characterized by an arsonium headgroup linked, via a phosphoramidate linker, to an unconventional lipidic moiety consisting of two diunsaturated linoleic chains. Physicochemical studies allowed us to comparatively evaluate the specific fluidity and fusogenicity properties of the liposomes formed. Although corresponding lipoplexes exhibited significant but relatively modest in vitro transfection efficiencies, they showed a remarkably efficient and reproducible ability to transfect mouse lung, with in vivo transfection levels higher than those observed with a monounsaturated analogue previously described. Thus, these results demonstrate that this diunsaturated cationic lipophosphoramidate constitutes an efficient and versatile nonviral vector for gene transfection. They also invite further evaluations of the transfection activity, especially in vivo, of gene delivery systems incorporating the lipid reported herein and/or other lipids bearing polyunsaturated chains.Journal of Medicinal Chemistry 02/2010; 53(4):1496-508. · 4.80 Impact Factor -
Article: Caecum: A Potential Site for Studying Gene Transfer in vivo
[show abstract] [hide abstract]
ABSTRACT: Abstract Over the past years we have designed and synthesized a new class of synthetic vectors called phosphonolipids and then shown their ability to transfect lungs cells of mice with efficiency. One of them, GLB73, gave high levels of transfection. In the study reported here, we explored the potential of caecum as an alternative site for studying the feasibility of gene transfer in this site. Transfections were performed by using two reporter genes encoding for (igalactosidase and luciferase; transfection activity was assessed using two tests: chemiluminescent and cytofiuorimetric assays. The results obtained showed successful gene transfer into the caecum: up to 27% cells were LacZ+ with a mean of 11%; the maximum of efficiency was also observed 3 days after transfection which then decreased until day 7. Our lipoplex was 8-fold more efficient than the naked DNA (Mann Whitney test; p = 0.03). Moreover, we were able to visually follow the uptake of lipoplexes by enterocytes from 30 mn to 3 days post transfection. So, this study constituted an encouraging first step in the assessment of the caecum as a potential model for gene transfer. In the near future, further electrophysiological studies using the gene of interest as CFTR gene should be performed in the caecum.09/2008; 10(1):61-71. -
Article: Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients.
Bone marrow transplantation 09/2011; 47(6):874-6. · 3.00 Impact Factor -
Article: Delayed G-CSF stimulation after PBSCT does not seem to modify the biological parameters of bone marrow recovery.
[show abstract] [hide abstract]
ABSTRACT: There are currently no recommendations indicating when stimulation should begin after autologous peripheral blood stem cell transplantation (PBSCT). We compared the outcome following between two treatment groups, in which daily granulocyte colony stimulating factor (G-CSF) administration began on either the fifth or the eighth day after PBSCT in lymphoma and myeloma patients. We studied eight clinical parameters: number of G-CSF injections, number of days of hospitalization, of red blood cell or platelet transfusions; days when body temperature exceeds 38°C; days of parenteral nutrition; weight loss and hospitalization costs. We studied also four biological parameters: number of CD34+ cells, days with leucocytes less than 1 × 10(9) /L, days with hemoglobin less than 90 g/L or with less than 50 × 10(9) /L of platelets. There were no statistical significant differences between the study arms. It seems that delayed stimulation by G-CSF after PBSCT is safety and does not seem to modify bone marrow recovery timing.American Journal of Hematology 04/2011; 86(4):351-2. · 4.67 Impact Factor
